Navigation Links
OctreoPharm Sciences Receives Orphan Drug Designation for SOMscan® for the Diagnosis of Neuroendocrine Tumours
Date:10/12/2011

BERLIN, October 12, 2011 /PRNewswire/ --

OctreoPharm Sciences GmbH, a Berlin based specialist for radiopharmaceuticals, announced today that the European Medicines Agency has granted Orphan Drug status to OctreoPharm Sciences product SOMscan® for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours.

The Orphan Drug status entitles OctreoPharm Sciences to ten year market exclusivity in Europe following marketing approval for SOMscan®. The designation also provides for special benefits, including possible exemptions in certain regulatory fees during development.

"We are proud to have received this Orphan Drug Designation for the diagnosis of gastro-entero-pancreatic neuroendocrine tumours" said Dr. Hakim Bouterfa, Managing Director and Head of R&D. Udo Blaseg, Managing Director and Head of Operations added: "This designation is an important step for a new and heavily improved diagnostic and staging tool for a seriously debilitating and potentially lethal disease."

About SOMscan™

SOMscan is a new Gallium-68-labeled radioactive contrast agent for positron emission tomography with the potential to detect neuroendocrine tumors currently in Phase I. It binds to four out of five specific tumor receptor subtypes on the surface of neuroendocrine tumors. This may allow detection of neuroendocrine tumors which previously escaped discovery in imaging. The diagnosis of neuroendocrine tumors with SOMscan has the potential to be faster, more accurate, more reliable and more specific.

About OctreoPharm Sciences GmbH

OctreoPharm Sciences GmbH is a privately held clinical development company focusing on radiopharmaceuticals for the diagnosis and therapeutic control of tumors. The company intends to acquire licenses for other product candidates as well. OctreoPharm Sciences is in particular on the lookout for collaborations with pharmaceutical companies which focus on products for personalized medicine and new therapeutic agents.

Contact:
Udo Blaseg
OctreoPharm Sciences GmbH
Robert-Rössle-Straße 10
13125 Berlin
Phone:  +49(0)30-9489-3360
eMail:  info@octreopharm.com



'/>"/>
SOURCE OctreoPharm
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OctreoPharm Sciences GmbH Granted Global and Exclusive License for Oncology Diagnostic Product
2. Intellect Neurosciences CEO to be Featured on Wall Street Reporter
3. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
4. SV Life Sciences Appoints Veteran Diagnostics Professional Dr. Heiner Dreismann as Venture Partner
5. Particle Sciences Granted Patent on Self Sterilizing Medical Devices
6. Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement
7. Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
8. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
9. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
10. BD Biosciences Introduces New Device Designed to Increase Cell Growth and Cell Culture Productivity
11. Neurocrine Biosciences Announces Elagolix Scientific Presentations at the 67th Annual Meeting of the American Society for Reproductive Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... IRVING, Texas , Oct. 6, 2017   ... industry with more than $100 billion in purchasing power, ... industry news and information. The Newsroom is ... chain and industry trends, infographics, expert bios, news releases, ... Besides having access to a wealth of resources at ...
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
Breaking Medicine News(10 mins):